TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- Known as:
- TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- Catalog number:
- 10428-RP02
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
Related genes to: TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- Gene:
- TACSTD2 NIH gene
- Name:
- tumor associated calcium signal transducer 2
- Previous symbol:
- M1S1
- Synonyms:
- TROP2, GA733-1, EGP-1
- Chromosome:
- 1p32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-11-20
- Date modifiied:
- 2019-03-01
Related products to: TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
Related articles to: TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- The gene solute carrier family 52 member 3 (SLC52A3) encodes riboflavin transporter-3, a transmembrane protein essential for riboflavin absorption. Emerging evidence suggests that metabolic transporters may play a role in tumor biology. This study aimed to investigate the expression patterns, prognostic significance, genetic alterations, and functional associations of SLC52A3 in gynecological cancers. - Source: PubMed
Publication date: 2026/06/07
Cecati MoniaSchiavoni ValentinaCampagna RobertoTossetta Giovanni - Keratoconus is a corneal disorder that causes thinning and bulging of the cornea, resulting in astigmatism and other refractive errors. Mechanical effects and environmental factors are known to exacerbate the disease, and genetic predisposition plays a significant role in its development. This study investigated the presence of genetic variants in 32 keratoconus patients. We used a next-generation sequencing-based method, and variant interpretation was performed according to the American College of Medical Genetics and Genomics (ACMG) guidelines. Variants were prioritized based on multiple criteria, including population frequency data from the Genome Aggregation Database (gnomAD) (minor allele frequency < 1%), variant type and predicted functional effect, gene-disease association, inheritance pattern, phenotypic relevance, and in silico prediction tools. Thirteen variants were identified in 11 patients (34.3%). Two patients carried variants in two different genes, raising the possibility of oligogenic contributions. Ten variants (76.9%) were novel. The variants were detected in 12 genes, namely , , , , , , , , , , , and . No association was observed between detected variants and patient age. Our findings demonstrate a substantial proportion of novel variants and support the genetic heterogeneity of keratoconus, while also raising the possibility of oligogenic contributions in a subset of patients. - Source: PubMed
Publication date: 2026/05/27
Paksoy BarısDogan BernaCengiz Ünal AyşeKizildag Ozbay Esra - Early and minimally invasive detection of colorectal neoplasia remains a major challenge in cancer prevention. Current blood-based screening approaches lack sufficient sensitivity for early-stage lesions and advanced adenomas, highlighting the need for novel circulating biomarkers. - Source: PubMed
Publication date: 2026/06/25
Balounova KaterinaUttarilli AnushaHorak JosefMakajevova VeronikaSojka LadislavSimsa JaromirBruha JanLiska VaclavSelvi SabaKorenkova VlastaVodenkova SonaJungwirth JiriMacinga PeterHucl TomasKral JanSchneiderova MichaelaValickova AnnaVymetalkova Veronika - Antibody-drug conjugates (ADCs) target surface proteins on cancer cells, leading to internalization and delivery of a drug payload, thereby enhancing selectivity and minimizing toxicity. ADCs against TROP2 (Sacituzumab govitecan) or HER2 (T-DXd) have demonstrated efficacy in metastatic breast cancer, yet paradoxically, outside of -amplified breast cancers, expression levels of these breast cancer-enriched epitopes in tumor biopsies have not been strongly correlated with clinical response. We undertook serial quantitative imaging of circulating tumor cells (CTCs) in a prospective cohort of 35 patients treated with either of these ADCs. At the single-cell level, expression of TROP2 and HER2 within individual patients is highly heterogeneous in both CTCs and paired tumor biopsies. Measurement of these epitopes on CTCs immediately prior to ADC therapy does not predict depth of clinical response. However, absence of CTCs or >80% reduction in CTC numbers after three weeks of treatment (CTC) predicts durable response, compared with CTC cases (TROP2: HR 5.15, = 0.012; HER2: HR 6.01, < 0.001). Targeted epitopes are not commonly downregulated on CTCs at the time of acquired clinical resistance, and switching between TROP2- and HER2-targeting ADCs sharing similar payloads infrequently leads to second-line response. Thus, while CTC burden is correlated with response to these ADCs, the level of TROP2 or HER2 expression is poorly predictive. These findings point to sensitivity to the drug payload as a potential driver of clinical response to currently approved ADCs in breast cancer. - Source: PubMed
Publication date: 2026/06/17
Mishra AvanishAbelman Rachel OCunneely QuinnPutaturo VictorDeshpande Akansha ABell RemySeider Elizabeth MXu Katherine HShan MythreayiKelly JustinHuang Shih-BoRieur OliviaKnape JustineGopinathan Kaustav AKikkeri KruthikaEdd Jon FWalsh JohnDai Charles SEllisen Leif WTing David TNieman LindaToner MehmetBardia AdityaHaber Daniel AMaheswaran Shyamala - Trop2-directed antibody-drug conjugates (ADCs) show activity across epithelial cancers, yet determinants of target expression in tumors and normal tissues remain poorly defined. We integrated bulk and single-cell transcriptomic profiles from over 20,000 samples across TCGA, GTEx and public atlases to map TACSTD2 expression, regulation and functional correlates in solid malignancies and healthy epithelia. TACSTD2 was restricted to epithelial lineages, enriched in multiple tumors and detectable in selected normal epithelia. Genomic alterations were uncommon, whereas DNA methylation showed a consistent inverse association with expression, indicating dominant epigenetic control. TACSTD2 expression was linked to epithelial programs shaping the tumor microenvironment, including pathways related to barrier integrity and variable immune interactions across tumor types, with potential implications for combination with immune-checkpoint inhibitors. Across histologies, TACSTD2 showed modest and context-dependent co-expression with genes involved in ADC-processing and payload sensitivity. These findings indicate that antigen abundance alone is insufficient to predict ADC efficacy or toxicity across histologies. - Source: PubMed
Publication date: 2026/06/15
Notini GiuliaGalbardi BarbaraViale GiuliaNaldini Matteo MBosi CarloDe Micheli GiacomoLicata LucaMariani MarcoPiras MartaCriscitiello CarmenBarreca MarcoCallari MaurizioZanibelli CaterinaPatanè FrancescaChiavassa AntonellaPérez-García José ManuelAli H RazaCórtes JavierPusztai LajosGianni LucaBianchini GiampaoloDugo Matteo